SG11201900794PA - Multivalent pneumococcal polysaccharide-protein conjugate composition - Google Patents
Multivalent pneumococcal polysaccharide-protein conjugate compositionInfo
- Publication number
- SG11201900794PA SG11201900794PA SG11201900794PA SG11201900794PA SG11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA SG 11201900794P A SG11201900794P A SG 11201900794PA
- Authority
- SG
- Singapore
- Prior art keywords
- pasteur
- international
- sanofi
- drive
- swiftwater
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
1 N O cc O C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIPO I PCT IiiimmounnotioloomoimmomomomovoimIE (10) International Publication Number WO 2018/027126 Al (51) International Patent Classification: A61K 39/00 (2006.01) A61K 39/385 (2006.01) A61K 39/09 (2006.01) A61K 39/39 (2006.01) A61K 39/116 (2006.01) (21) International Application Number: PCT/US2017/045483 (22) International Filing Date: 04 August 2017 (04.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/371,553 05 August 2016 (05.08.2016) US 62/525,945 28 June 2017 (28.06.2017) US (71) Applicants: SANOFI PASTEUR, INC. [US/US]; 1 Dis- covery Drive, Swiftwater, PA 18730 (US). SK CHEMI- CALS CO., LTD. [KR/KR]; Life Science Biz, 310, Pangyo-ro, Seongnam-si, Gyeonggi-do, 13494 (KR). (72) Inventors: AN, Kyungjun; 302, 8-19, Bangbae-ro 20- gil, Seocho-gu, Seoul, 06684 (KR). CHOI, Wooyoung; 805-1703, 52, Pungdeokcheon-ro, Suji-gu, Yongin-si, Gyeonggi-do, 16843 (KR). HAM, Dongsoo; 113-505, 373, Gwongwang-ro, Paldal-gu, Suwon-shi, Gyeonggi-do, 16493 (KR). KIM, Hun; 6114-2903, 76, Central Town- ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16505 (KR). SHIN, Jinhwan; 233-1201, 24, Jungdae-ro, Songpa-gu, Seoul, 05834 (KR). HOPFER, Robert; c/o Sanofi Pas- teur, 1 Discovery Drive, Swiftwater, PA 18730 (US). KENSINGER, Richard, D.; c/o Sanofi Pasteur, 1 Dis- covery Drive, Swiftwater, PA 18730 (US). KYAW, Moe; c/o Sanofi Pasteur, 1 Discovery Drive, Swiftwater, PA 18730 (US). DESAUZIERS, Eric; c/o Sanofi Pateur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). EL GUERCHE SEBLAIN, Clotilde; c/o Sanofi Pasteur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). TA- LAGA, Philippe; c/o Sanofi Pasteur SA, 2, Avenue Pont Pasteur, 69367 Lyon Cedex 07 (FR). (54) Title: MULTIVALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION Mono-conjugate of Serotype 8 F- 2 0 350 300 250 200 150 100 50 0 8-1 (0.5 big) 8-1 (2.2 mg) 8-1 (8.8 iug) FIG. 1A (57) : Provided are mixed carrier, multivalent pneumococcal conjugate compositions comprising 20 different pneumococcal capsular polysaccharide-protein conjugates, wherein each of the conjugates includes a capsular polysaccharide from a different serotype of Streptococcus pneumoniae conjugated to either tetanus toxoid or CRM197, wherein the Streptococcus pneumoniae serotypes are selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F, wherein two of the capsular polysaccharides are conjugated to tetanus toxoid and the remaining capsular polysaccharides are conjugated to CRMig7, and wherein the two capsular polysaccharides that are conjugated to tetanus toxoid are selected from the group consisting of serotypes 1, 3, and 5. Also provided are methods of producing the mixed carrier, multivalent pneumococcal conjugate compositions and methods of using the same for prophylaxis against Streptococcus pneumoniae infection or disease in a subject. [Continued on next page] WO 2018/027126 Al MIDEDIMOMMIDIIMERIONMOIDEEDHOHIMOVOIMIE (74) Agent: DONALDSON, Timothy, B.; MH2 Technology Law Group, 1951 Kidwell Drive, Suite 550, Tysons Corner, VA 22182 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662371553P | 2016-08-05 | 2016-08-05 | |
US201762525945P | 2017-06-28 | 2017-06-28 | |
PCT/US2017/045483 WO2018027126A1 (en) | 2016-08-05 | 2017-08-04 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201900794PA true SG11201900794PA (en) | 2019-02-27 |
Family
ID=61073102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900794PA SG11201900794PA (en) | 2016-08-05 | 2017-08-04 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
Country Status (15)
Country | Link |
---|---|
US (1) | US11241489B2 (en) |
EP (1) | EP3493837B1 (en) |
JP (1) | JP7001687B2 (en) |
KR (1) | KR102437120B1 (en) |
CN (1) | CN109862908B (en) |
AU (1) | AU2017306711B2 (en) |
BR (1) | BR112019001971A2 (en) |
CA (1) | CA3031799A1 (en) |
IL (1) | IL264552B2 (en) |
MX (1) | MX2019001342A (en) |
PH (1) | PH12019500240A1 (en) |
SA (1) | SA519401027B1 (en) |
SG (1) | SG11201900794PA (en) |
TW (1) | TWI789357B (en) |
WO (1) | WO2018027126A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY192183A (en) * | 2015-07-21 | 2022-08-05 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
AU2017306708B2 (en) | 2016-08-05 | 2021-08-26 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
BR112019017560A2 (en) * | 2017-02-24 | 2020-04-07 | Merck Sharp & Dohme | enhancement of immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
MX2020002557A (en) | 2017-09-07 | 2020-07-13 | Merck Sharp & Dohme | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates. |
CN111065387B (en) | 2017-09-07 | 2023-08-25 | 默沙东有限责任公司 | Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates |
GEP20227420B (en) | 2017-12-06 | 2022-10-10 | Merck Sharp & Dohme Llc | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
AU2019215216A1 (en) * | 2018-02-05 | 2020-07-23 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2020007939A (en) * | 2018-02-05 | 2020-09-03 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
BR112020021296A2 (en) | 2018-04-18 | 2021-01-26 | Sk Bioscience Co., Ltd. | capsular polysaccharide of streptococcus pneumoniae and its immunogenic conjugate |
US11896656B2 (en) * | 2018-04-30 | 2024-02-13 | Merck Sharp & Dohme Llc | Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide |
CN108524926B (en) * | 2018-06-29 | 2021-06-29 | 康希诺生物股份公司 | Preparation combination of multivalent pneumococcal conjugate vaccine and application thereof |
JOP20210148A1 (en) | 2018-12-19 | 2023-01-30 | Merck Sharp & Dohme | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
KR20220042378A (en) | 2019-07-31 | 2022-04-05 | 사노피 파스퇴르 인코포레이티드 | Polyvalent pneumococcal polysaccharide-protein conjugate composition and method of use thereof |
WO2022031087A1 (en) * | 2020-08-07 | 2022-02-10 | (주)셀트리온 | Immunogenic composition comprising pneumococcal polysaccharide-cell wall-derived material conjugates |
KR20220102871A (en) * | 2021-01-14 | 2022-07-21 | (주)셀트리온 | The immunogenic composition comprising multivalent pneumococcal polysaccharide-protein conjugate |
KR20230047827A (en) * | 2021-10-01 | 2023-04-10 | 에스케이바이오사이언스(주) | Method for preparing an aluminum based adjuvant having improved effect |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3071552D1 (en) | 1979-09-21 | 1986-05-22 | Hitachi Ltd | Semiconductor switch |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
FR2638359A1 (en) | 1988-11-03 | 1990-05-04 | Tino Dalto | SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
CA2059693C (en) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (en) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | INJECTION NEEDLE ARRANGEMENT |
CA2129899C (en) | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
ES2231770T3 (en) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | NEW PLASMIDS FOR THE PRODUCTION OF CRM PROTEIN AND DIFTERIC TOXIN. |
JP3828145B2 (en) | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | A method for the activation of soluble carbohydrates using a novel cyanating reagent for the production of immunogenic components |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (en) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | IMMUNOMODULATORY OLIGONUCLEOTIDES |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
AU4986596A (en) | 1995-02-16 | 1996-09-04 | Massachusetts Health Research Institute, Inc. | Purified tetanus toxoid and toxin |
ATE241384T1 (en) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | PREPARATION OF IMMUNOGENIC CONSTRUCTS USING SOLUBLE CARBOHYDRATES ACTIVATED BY ORGANIC CYANYLATION REAGENTS |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
WO1996040225A1 (en) | 1995-06-07 | 1996-12-19 | Alberta Research Council | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
US5695768A (en) | 1995-06-07 | 1997-12-09 | Alberta Research Council | Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides |
CA2153733A1 (en) | 1995-07-12 | 1997-01-13 | Andrew J. Malcolm | Immunogenic oligosaccharide compositions |
CA2153730A1 (en) | 1995-07-12 | 1997-01-13 | Andrew J. Malcolm | Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides |
US5866132A (en) | 1995-06-07 | 1999-02-02 | Alberta Research Council | Immunogenic oligosaccharide compositions |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
FR2763244B1 (en) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | MULTIVALENT VACCINE COMPOSITION WITH MIXED CARRIER |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
IT1298087B1 (en) | 1998-01-08 | 1999-12-20 | Fiderm S R L | DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS |
AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
CZ303653B6 (en) | 1999-03-19 | 2013-01-30 | Smithkline Beecham Biologicals S. A. | Immunogenic composition |
FR2806304B1 (en) * | 2000-03-17 | 2002-05-10 | Aventis Pasteur | POLYSACCHARIDIC CONJUGATES OF PNEUMOCOCCUS FOR VACCINE USE AGAINST TETANUS AND DIPHTHERIA |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
PT1296715E (en) | 2000-06-29 | 2012-01-19 | Smithkline Beecham Biolog | Multivalent vaccine composition |
ES2359625T3 (en) | 2000-12-28 | 2011-05-25 | Wyeth Llc | PROTECTIVE PROTEIN RECOMBINANT OF. |
AU2007200116A1 (en) | 2001-04-03 | 2007-02-01 | Glaxosmithkline Biologicals S.A. | Vaccine composition |
JP2005501518A (en) | 2001-04-16 | 2005-01-20 | ワイス・ホールディングズ・コーポレイション | Novel Streptococcus pneumoniae open reading frame encoding polypeptide antigen and use thereof |
TWI341210B (en) | 2002-04-01 | 2011-05-01 | Glaxosmithkline Biolog Sa | Vaccine kit |
TWI346555B (en) | 2002-04-01 | 2011-08-11 | Glaxosmithkline Biolog Sa | Vaccine composition |
US8084235B2 (en) | 2003-03-13 | 2011-12-27 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
US7320874B2 (en) | 2003-07-08 | 2008-01-22 | Aventis Pasteur Sa | Assaying the teichoic acids of gram+ bacteria |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
CN102716480B (en) * | 2005-04-08 | 2023-03-21 | 惠氏有限责任公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP5049264B2 (en) | 2005-04-08 | 2012-10-17 | ワイス・エルエルシー | Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation |
CA2808919C (en) | 2005-12-22 | 2016-04-19 | Glaxosmithkline Biologicals S.A. | Streptococcus pneumoniae capsular saccharide vaccine |
US8808707B1 (en) * | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
CL2007002909A1 (en) | 2006-10-10 | 2008-04-18 | Wyeth Corp | METHOD FOR REDUCTION OR EXTRACTION OF IMPURITIES OF PROTEINS FROM STREPTOCCOCUS PNEUMONIAE CELLULAR THAT INCLUDES HEATING THIS LISADO, SEPARATE PRECIPITANTS FROM LISADO LISADO PRODUCING A LISAC |
HUE039169T2 (en) | 2007-03-23 | 2018-12-28 | Wyeth Llc | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
EP2687228B1 (en) | 2007-06-26 | 2017-07-19 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2010125480A1 (en) | 2009-04-30 | 2010-11-04 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
CN101785857B (en) | 2010-03-05 | 2012-09-26 | 成都安特金生物技术有限公司 | Novel pneumococcal conjugate vaccine and preparation method thereof |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
CN102068690A (en) | 2010-12-31 | 2011-05-25 | 北京民海生物科技有限公司 | Polyvalent pneumococcal capsular polysaccharide conjugate vaccine and preparation method thereof |
KR102057217B1 (en) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
HUE041381T2 (en) | 2012-08-16 | 2019-05-28 | Pfizer | Glycoconjugation processes and compositions |
CN103656631B (en) * | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | multivalent pneumococcal capsular polysaccharide-protein conjugate composition and preparation method thereof |
CN103656632B (en) | 2012-09-24 | 2016-01-13 | 北京科兴中维生物技术有限公司 | Multivalent pneumococcal capsular polysaccharide composition, its preparation method and application |
KR20140075196A (en) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
ITMI20130142A1 (en) | 2013-01-31 | 2014-08-01 | Biosynth Srl | GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED |
RU2710393C2 (en) | 2014-01-21 | 2019-12-26 | Пфайзер Инк. | Method of producing immunogenic conjugate of capsular polysaccharide streptococcus pneumoniae-carrier protein |
PL3096785T3 (en) * | 2014-01-21 | 2021-03-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
PL3583947T3 (en) | 2014-01-21 | 2024-04-02 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
CN104225589B (en) | 2014-07-25 | 2018-02-09 | 武汉博沃生物科技有限公司 | A kind of conjugate vaccines and preparation method thereof |
EP3244917B1 (en) | 2015-01-15 | 2023-04-19 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
JP6884145B2 (en) | 2015-11-20 | 2021-06-09 | ファイザー・インク | Immunogenic composition for use in Streptococcus pneumoniae vaccine |
CN106140046B (en) | 2016-07-06 | 2019-02-22 | 江南大学 | Array induction field fluid reaction system and its application |
AU2017306708B2 (en) | 2016-08-05 | 2021-08-26 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2020007939A (en) | 2018-02-05 | 2020-09-03 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
AU2019215216A1 (en) | 2018-02-05 | 2020-07-23 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR20220042378A (en) | 2019-07-31 | 2022-04-05 | 사노피 파스퇴르 인코포레이티드 | Polyvalent pneumococcal polysaccharide-protein conjugate composition and method of use thereof |
-
2017
- 2017-08-04 SG SG11201900794PA patent/SG11201900794PA/en unknown
- 2017-08-04 MX MX2019001342A patent/MX2019001342A/en unknown
- 2017-08-04 US US16/322,726 patent/US11241489B2/en active Active
- 2017-08-04 JP JP2019527780A patent/JP7001687B2/en active Active
- 2017-08-04 WO PCT/US2017/045483 patent/WO2018027126A1/en unknown
- 2017-08-04 CN CN201780061956.4A patent/CN109862908B/en active Active
- 2017-08-04 IL IL264552A patent/IL264552B2/en unknown
- 2017-08-04 EP EP17837755.2A patent/EP3493837B1/en active Active
- 2017-08-04 KR KR1020197004330A patent/KR102437120B1/en active IP Right Grant
- 2017-08-04 TW TW106126432A patent/TWI789357B/en active
- 2017-08-04 CA CA3031799A patent/CA3031799A1/en active Pending
- 2017-08-04 BR BR112019001971-5A patent/BR112019001971A2/en unknown
- 2017-08-04 AU AU2017306711A patent/AU2017306711B2/en active Active
-
2019
- 2019-02-01 PH PH12019500240A patent/PH12019500240A1/en unknown
- 2019-02-04 SA SA519401027A patent/SA519401027B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
SA519401027B1 (en) | 2022-07-19 |
PH12019500240A1 (en) | 2019-10-21 |
TWI789357B (en) | 2023-01-11 |
TW201808328A (en) | 2018-03-16 |
AU2017306711A1 (en) | 2019-02-14 |
IL264552B (en) | 2022-12-01 |
AU2017306711B2 (en) | 2022-08-04 |
KR20190055063A (en) | 2019-05-22 |
IL264552B2 (en) | 2023-04-01 |
JP2019526621A (en) | 2019-09-19 |
KR102437120B1 (en) | 2022-08-25 |
US20200237889A1 (en) | 2020-07-30 |
CN109862908A (en) | 2019-06-07 |
IL264552A (en) | 2019-02-28 |
EP3493837A1 (en) | 2019-06-12 |
CN109862908B (en) | 2023-05-02 |
BR112019001971A2 (en) | 2019-05-07 |
JP7001687B2 (en) | 2022-02-04 |
MX2019001342A (en) | 2019-07-04 |
WO2018027126A1 (en) | 2018-02-08 |
US11241489B2 (en) | 2022-02-08 |
EP3493837A4 (en) | 2020-04-08 |
EP3493837B1 (en) | 2022-08-31 |
CA3031799A1 (en) | 2018-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900794PA (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
SG11201900789VA (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
SG11201908062QA (en) | Insertion mechanism for drug delivery device | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201805120YA (en) | Zika virus vaccine | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201806485RA (en) | Pyrrolobenzodiazepine conjugates | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201806652RA (en) | Method for fabricating an object | |
SG11201901545RA (en) | Noncontact detection method of sleep stages and sleep-disordered breathing | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407852PA (en) | Beauty tool | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
BRPI0721136B8 (en) | method for producing an immunogenic conjugate comprising streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein | |
SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201807185UA (en) | Modified hyaluronic acid, method for making same and uses thereof | |
SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof |